annual EBIT:
-$235.52M+$76.78M(+24.59%)Summary
- As of today (May 29, 2025), ALNY annual earnings before interest & taxes is -$235.52 million, with the most recent change of +$76.78 million (+24.59%) on December 31, 2024.
- During the last 3 years, ALNY annual EBIT has risen by +$473.61 million (+66.79%).
- ALNY annual EBIT is now -5478.33% below its all-time high of -$4.22 million, reached on December 31, 2002.
Performance
ALNY EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$2.95M+$152.04M(+98.10%)Summary
- As of today (May 29, 2025), ALNY quarterly earnings before interest & taxes is -$2.95 million, with the most recent change of +$152.04 million (+98.10%) on March 31, 2025.
- Over the past year, ALNY quarterly EBIT has increased by +$25.38 million (+89.59%).
- ALNY quarterly EBIT is now -101.62% below its all-time high of $181.63 million, reached on September 30, 2023.
Performance
ALNY quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$210.13M+$25.38M(+10.78%)Summary
- As of today (May 29, 2025), ALNY TTM earnings before interest & taxes is -$210.13 million, with the most recent change of +$25.38 million (+10.78%) on March 31, 2025.
- Over the past year, ALNY TTM EBIT has dropped by -$12.91 million (-6.55%).
- ALNY TTM EBIT is now -404.36% below its all-time high of $69.04 million, reached on June 30, 2024.
Performance
ALNY TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ALNY EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.6% | +89.6% | -6.5% |
| 3 y3 years | +66.8% | +98.5% | +71.6% |
| 5 y5 years | +73.4% | +98.4% | +76.3% |
ALNY EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +75.8% | -101.6% | +99.2% | -404.4% | +79.3% |
| 5 y | 5-year | at high | +75.8% | -101.6% | +99.2% | -404.4% | +79.3% |
| alltime | all time | -5478.3% | +75.8% | -101.6% | +99.2% | -404.4% | +79.3% |
ALNY EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$2.95M(-98.1%) | -$210.13M(-10.8%) |
| Dec 2024 | -$235.52M(-24.6%) | -$154.99M(+108.6%) | -$235.52M(+26.0%) |
| Sep 2024 | - | -$74.29M(-436.3%) | -$186.88M(-370.7%) |
| Jun 2024 | - | $22.09M(-178.0%) | $69.04M(-135.0%) |
| Mar 2024 | - | -$28.33M(-73.4%) | -$197.22M(-36.8%) |
| Dec 2023 | -$312.30M(-67.8%) | -$106.35M(-158.6%) | -$312.30M(-18.5%) |
| Sep 2023 | - | $181.63M(-174.4%) | -$383.06M(-58.8%) |
| Jun 2023 | - | -$244.17M(+70.3%) | -$929.55M(+1.3%) |
| Mar 2023 | - | -$143.41M(-19.0%) | -$917.44M(-5.5%) |
| Dec 2022 | -$971.02M(+36.9%) | -$177.11M(-51.5%) | -$971.02M(-4.6%) |
| Sep 2022 | - | -$364.86M(+57.2%) | -$1.02B(+24.6%) |
| Jun 2022 | - | -$232.06M(+17.8%) | -$816.51M(+10.4%) |
| Mar 2022 | - | -$196.99M(-11.9%) | -$739.36M(+4.3%) |
| Dec 2021 | -$709.12M(-8.0%) | -$223.49M(+36.3%) | -$709.12M(+1.2%) |
| Sep 2021 | - | -$163.96M(+5.8%) | -$700.72M(-7.9%) |
| Jun 2021 | - | -$154.91M(-7.1%) | -$760.48M(+0.6%) |
| Mar 2021 | - | -$166.76M(-22.5%) | -$756.22M(-1.9%) |
| Dec 2020 | -$771.10M(-12.9%) | -$215.08M(-3.9%) | -$771.10M(-7.4%) |
| Sep 2020 | - | -$223.72M(+48.5%) | -$832.61M(+1.8%) |
| Jun 2020 | - | -$150.66M(-17.1%) | -$817.81M(-7.7%) |
| Mar 2020 | - | -$181.65M(-34.3%) | -$885.68M(-0.8%) |
| Dec 2019 | -$885.25M(+16.4%) | -$276.58M(+32.4%) | -$892.82M(+14.1%) |
| Sep 2019 | - | -$208.93M(-4.4%) | -$782.60M(-5.5%) |
| Jun 2019 | - | -$218.52M(+15.7%) | -$828.22M(+3.3%) |
| Mar 2019 | - | -$188.79M(+13.5%) | -$802.06M(+5.4%) |
| Dec 2018 | -$760.67M(+52.1%) | -$166.36M(-34.6%) | -$760.67M(+2.6%) |
| Sep 2018 | - | -$254.56M(+32.3%) | -$741.62M(+21.0%) |
| Jun 2018 | - | -$192.35M(+30.5%) | -$612.86M(+13.3%) |
| Mar 2018 | - | -$147.41M(+0.1%) | -$540.98M(+8.2%) |
| Dec 2017 | -$500.09M(+17.8%) | -$147.30M(+17.1%) | -$500.09M(+6.8%) |
| Sep 2017 | - | -$125.80M(+4.4%) | -$468.22M(+4.3%) |
| Jun 2017 | - | -$120.47M(+13.1%) | -$449.09M(+6.7%) |
| Mar 2017 | - | -$106.51M(-7.7%) | -$421.07M(-0.8%) |
| Dec 2016 | -$424.59M(+43.4%) | -$115.43M(+8.2%) | -$424.59M(+5.7%) |
| Sep 2016 | - | -$106.68M(+15.4%) | -$401.67M(+7.6%) |
| Jun 2016 | - | -$92.45M(-16.0%) | -$373.32M(+5.5%) |
| Mar 2016 | - | -$110.03M(+18.9%) | -$353.81M(+19.5%) |
| Dec 2015 | -$296.01M(+60.7%) | -$92.51M(+18.1%) | -$296.01M(+18.8%) |
| Sep 2015 | - | -$78.33M(+7.4%) | -$249.21M(+15.3%) |
| Jun 2015 | - | -$72.94M(+39.7%) | -$216.08M(+12.5%) |
| Mar 2015 | - | -$52.22M(+14.2%) | -$192.03M(+4.2%) |
| Dec 2014 | -$184.21M(+98.2%) | -$45.71M(+1.1%) | -$184.21M(+9.6%) |
| Sep 2014 | - | -$45.20M(-7.6%) | -$168.09M(+8.4%) |
| Jun 2014 | - | -$48.90M(+10.1%) | -$155.13M(+21.6%) |
| Mar 2014 | - | -$44.41M(+50.1%) | -$127.55M(+37.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$92.94M(+46.2%) | -$29.59M(-8.2%) | -$92.94M(+7.2%) |
| Sep 2013 | - | -$32.23M(+51.2%) | -$86.70M(+19.4%) |
| Jun 2013 | - | -$21.31M(+117.4%) | -$72.62M(+14.6%) |
| Mar 2013 | - | -$9.80M(-58.0%) | -$63.37M(-0.3%) |
| Dec 2012 | -$63.57M(+16.0%) | -$23.35M(+28.7%) | -$63.57M(+18.2%) |
| Sep 2012 | - | -$18.15M(+50.4%) | -$53.80M(+11.9%) |
| Jun 2012 | - | -$12.07M(+20.7%) | -$48.09M(-2.1%) |
| Mar 2012 | - | -$10.00M(-26.4%) | -$49.14M(-10.4%) |
| Dec 2011 | -$54.82M(+25.3%) | -$13.59M(+9.2%) | -$54.82M(+2.8%) |
| Sep 2011 | - | -$12.44M(-5.2%) | -$53.31M(+7.5%) |
| Jun 2011 | - | -$13.12M(-16.3%) | -$49.60M(+3.1%) |
| Mar 2011 | - | -$15.68M(+29.8%) | -$48.11M(+10.0%) |
| Dec 2010 | -$43.74M(-7.0%) | -$12.08M(+38.4%) | -$43.74M(+13.2%) |
| Sep 2010 | - | -$8.73M(-24.9%) | -$38.63M(-2.3%) |
| Jun 2010 | - | -$11.63M(+2.8%) | -$39.55M(-21.4%) |
| Mar 2010 | - | -$11.31M(+62.3%) | -$50.33M(+7.1%) |
| Dec 2009 | -$47.01M(+90.6%) | -$6.97M(-27.8%) | -$47.01M(+5.2%) |
| Sep 2009 | - | -$9.65M(-56.9%) | -$44.68M(+16.8%) |
| Jun 2009 | - | -$22.41M(+180.9%) | -$38.26M(+33.4%) |
| Mar 2009 | - | -$7.98M(+72.1%) | -$28.68M(+16.3%) |
| Dec 2008 | -$24.66M(-68.8%) | -$4.64M(+43.4%) | -$24.66M(+177.8%) |
| Sep 2008 | - | -$3.23M(-74.8%) | -$8.88M(-84.4%) |
| Jun 2008 | - | -$12.83M(+224.3%) | -$56.98M(-3.6%) |
| Mar 2008 | - | -$3.96M(-135.5%) | -$59.10M(-25.3%) |
| Dec 2007 | -$79.14M(+100.3%) | $11.15M(-121.7%) | -$79.14M(-21.1%) |
| Sep 2007 | - | -$51.34M(+243.3%) | -$100.28M(+74.3%) |
| Jun 2007 | - | -$14.95M(-37.7%) | -$57.54M(+7.2%) |
| Mar 2007 | - | -$23.99M(+140.2%) | -$53.70M(+35.9%) |
| Dec 2006 | -$39.50M(-9.1%) | -$9.99M(+16.1%) | -$39.50M(-11.1%) |
| Sep 2006 | - | -$8.60M(-22.5%) | -$44.43M(-4.4%) |
| Jun 2006 | - | -$11.11M(+13.4%) | -$46.49M(-0.2%) |
| Mar 2006 | - | -$9.80M(-34.3%) | -$46.59M(+7.2%) |
| Dec 2005 | -$43.47M(+34.7%) | -$14.92M(+39.8%) | -$43.47M(+27.5%) |
| Sep 2005 | - | -$10.67M(-4.8%) | -$34.09M(+14.2%) |
| Jun 2005 | - | -$11.20M(+67.7%) | -$29.84M(+16.5%) |
| Mar 2005 | - | -$6.68M(+20.8%) | -$25.61M(-20.6%) |
| Dec 2004 | -$32.26M(+57.8%) | -$5.53M(-13.9%) | -$32.26M(-31.8%) |
| Sep 2004 | - | -$6.43M(-7.9%) | -$47.31M(+15.8%) |
| Jun 2004 | - | -$6.97M(-47.7%) | -$40.84M(+14.6%) |
| Mar 2004 | - | -$13.33M(-35.2%) | -$35.65M(+51.2%) |
| Dec 2003 | -$20.45M(+384.3%) | -$20.58M(<-9900.0%) | -$23.59M(+684.6%) |
| Sep 2003 | - | $44.00K(-102.5%) | -$3.01M(-1.4%) |
| Jun 2003 | - | -$1.78M(+40.9%) | -$3.05M(+140.9%) |
| Mar 2003 | - | -$1.27M | -$1.27M |
| Dec 2002 | -$4.22M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual EBIT year-on-year change?
- What is Alnylam Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly EBIT year-on-year change?
- What is Alnylam Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM EBIT year-on-year change?
What is Alnylam Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of ALNY is -$235.52M
What is the all time high annual EBIT for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual earnings before interest & taxes is -$4.22M
What is Alnylam Pharmaceuticals annual EBIT year-on-year change?
Over the past year, ALNY annual earnings before interest & taxes has changed by +$76.78M (+24.59%)
What is Alnylam Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of ALNY is -$2.95M
What is the all time high quarterly EBIT for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly earnings before interest & taxes is $181.63M
What is Alnylam Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, ALNY quarterly earnings before interest & taxes has changed by +$25.38M (+89.59%)
What is Alnylam Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of ALNY is -$210.13M
What is the all time high TTM EBIT for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM earnings before interest & taxes is $69.04M
What is Alnylam Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, ALNY TTM earnings before interest & taxes has changed by -$12.91M (-6.55%)